<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Sun, 08 Nov 2009 23:08:55 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>Oncothyreon to present at BioCentury NewsMakers Conference</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3471181</guid>
      <description><![CDATA[SEATTLE, Sept. 10 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 16th Annual BioCentury NewsMakers in the Biotech Industry Conference on Sept. 16, 2009 in New York.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3471181>[More...]</a>]]></description>
      <pubDate>Thu, 10 Sep 2009 12:00:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONTY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3471181</link>
    </item>
    <item>
      <title>Oncothyreon to present at Rodman &amp; Renshaw Global Healthcare Conference</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3456368</guid>
      <description><![CDATA[SEATTLE, WA, Sept. 3 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman &amp; Renshaw 11th Annual Healthcare Conference taking place Sept. 9-11, 2009 in New York.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3456368>[More...]</a>]]></description>
      <pubDate>Thu, 03 Sep 2009 11:58:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONTY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3456368</link>
    </item>
    <item>
      <title>Oncothyreon announces closing of $15.0 million registered direct financing</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3405077</guid>
      <description><![CDATA[SEATTLE, Aug. 10 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of approximately 2.28 million shares of its common stock and warrants to purchase approximately 684,000 shares of its common stock for gross proceeds of approximately $15.0 million on August 7, 2009. Oncothyreon sold the shares and warrants for $6.5775 per unit (each unit consisting of one share and a warrant to purchase 0.30 shares of common stock). The exercise price of the warrants is $6.5775 per share. The warrants are exercisable at any time on or after the closing and on or prior to the second anniversary of the closing of the transaction on August 7, 2009. Oncothyreon plans to use the proceeds from this financing for ...<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3405077>[More...]</a>]]></description>
      <pubDate>Mon, 10 Aug 2009 11:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONTY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3405077</link>
    </item>
    <item>
      <title>Oncothyreon announces webcast of second quarter 2009 financial results conference call</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3397434</guid>
      <description><![CDATA[SEATTLE, Aug. 6 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its second quarter and year end 2009 financial results on Wednesday, August 12, 2009 after the close of the U.S. and Canadian markets. Following the release, Oncothyreon's management expects to discuss these financial results and give a general business update in a conference call at 4:30 p.m. EST.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3397434>[More...]</a>]]></description>
      <pubDate>Thu, 06 Aug 2009 11:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONTY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3397434</link>
    </item>
    <item>
      <title>Oncothyreon announces commitments to purchase $15.0 million of company securities in a registered direct financing</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3391624</guid>
      <description><![CDATA[SEATTLE, Aug. 4 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it has obtained commitments from several investors to purchase approximately 2.28 million shares of its common stock and warrants to purchase approximately 684,000 shares of its common stock for gross proceeds of approximately $15.0 million. The investors have agreed to purchase the shares and warrants for $6.5775 per unit (each unit consisting of one share and a warrant to purchase 0.30 shares of common stock). The exercise price of the warrants will be $6.5775 per share. The warrants will be exercisable at any time on or after the closing date and prior to the second anniversary of the closing of the transaction. The closing of the offering is expected to ...<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3391624>[More...]</a>]]></description>
      <pubDate>Tue, 04 Aug 2009 19:04:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONTY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3391624</link>
    </item>
    <item>
      <title>Oncothyreon appoints Diana Hausman as Vice President of Clinical Development</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3391721</guid>
      <description><![CDATA[SEATTLE, WA, Aug. 4 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the &quot;Company&quot;) today announced the appointment of Diana Hausman, M.D., as Vice President, Clinical Development at Oncothyreon. In this position, Dr. Hausman will be responsible for planning and implementing the clinical development program for the Company's pipeline of oncology product candidates.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3391721>[More...]</a>]]></description>
      <pubDate>Tue, 04 Aug 2009 11:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONTY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3391721</link>
    </item>
    <item>
      <title>Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3387729</guid>
      <description><![CDATA[SEATTLE, Aug. 3 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the &quot;Company&quot;) today announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in San Francisco on August 1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital Cancer Centre, Ottawa, Ontario, involved 16 patients who received treatment with Stimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer (NSCLC).<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3387729>[More...]</a>]]></description>
      <pubDate>Mon, 03 Aug 2009 11:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONTY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3387729</link>
    </item>
    <item>
      <title>Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3278672</guid>
      <description><![CDATA[SEATTLE, June 22 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the &quot;Company&quot;) today announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Stimuvax is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3278672>[More...]</a>]]></description>
      <pubDate>Mon, 22 Jun 2009 11:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONTY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3278672</link>
    </item>
    <item>
      <title>Oncothyreon appoints Scott Peterson as Vice President of Research and Development</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3302509</guid>
      <description><![CDATA[SEATTLE, June 15 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the &quot;Company&quot;) today announced the appointment of Scott Peterson, Ph.D., as Vice President, Research and Development at Oncothyreon. In this position, Dr. Peterson will be responsible for overseeing those pre-clinical and non-clinical research and development activities that will support the advancement of the Company's pipeline of oncology product candidates into late phase clinical trials.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3302509>[More...]</a>]]></description>
      <pubDate>Mon, 15 Jun 2009 11:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONTY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3302509</link>
    </item>
    <item>
      <title>Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3302462</guid>
      <description><![CDATA[SEATTLE, WA, May 30 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the &quot;Company&quot;) today announced that data from clinical trials for three of the Company's product candidates were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2009 in Orlando, Florida. The presentations included long-term safety data from the Phase 2b trial of Stimuvax(R) in patients with stage IIIB/IV non-small cell lung cancer, preliminary results from the Phase 1 trial of the phosphoinositide-3-kinase (PI-3 kinase) inhibitor PX-866 in patients with advanced malignancy, and final results from two Phase 1b trials of the thioredoxin inhibitor PX-12 in advanced cancer patients. ...<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3302462>[More...]</a>]]></description>
      <pubDate>Sat, 30 May 2009 11:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONTY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ONY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3302462</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=ONY" rel="self" type="application/rss+xml" />
  </channel>
</rss>